Tyrosine protein kinase inhibition and cancer |
| |
| Affiliation: | 1. Department of Computer Science, University of Illinois at Springfield, Springfield, IL USA;2. Department of Ultrasound, Second Affiliated Hospital of Harbin Medical University, Harbin, China;3. Department of Cardiology, First Affiliated Hospital of Harbin Medical University, Harbin, China;4. Oracle Corporation, Westminster, CO, USA;1. Institut National de l''Environnement Industriel et des Risques (INERIS), UMR-I 02 SEBIO, Parc Technologique Alata, BP 2, 60550 Verneuil-en-Halatte, France;2. Université de Reims Champagne-Ardenne (URCA), UMR-I 02 SEBIO, Moulin de la Housse, B.P. 1039, 51687 Reims, France;3. INERIS, Unit of Models for Ecotoxicology and Toxicology (METO), Parc Technologique Alata, BP 2, 60550 Verneuil-en-Halatte, France |
| |
| Abstract: | The various aspects of the research on tyrosine protein kinase inhibition and its connections with cancer are presented. The emphasis was made on the theoretical low toxic side effects of specific tyrosine protein kinase inhibitors. Particularly, the strategy of finding peptidic substrate-derived inhibitors or modulators is discussed, with an almost complete compendium of the tyrosine protein kinase peptidic substrates published so far. A series of data has been gathered that may serve as a basis for the discovery of selective and specific tyrosine protein kinase inhibitors by screening on molecular and cellular models. The potential of SH2 domain-interfering agents are also presented as a promising route to new anticancer compounds. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
